Angiokeratoma in Fabry Disease: Diagnostic but not Treatment Effectiveness Marker
Article Sidebar
Main Article Content
Abstract
Introduction: Fabry disease (FD) is a rare metabolic disorder that leads to severe morbidity and premature mortality as a result of cardiac, renal or cerebrovascular complications. Enzyme replacement therapy (ERT) has been shown to provide clinically important benefits, and treatment is likely to alter the natural history of FD.
Case Report: The authors describe a 7-year-old boy with FD. Vascular skin lesions were very helpful in guiding appropriate investigations leading to prompt diagnosis. Because of multisystem involvement, including signs of nephropathy, ERT was started. The boy showed catch-up growth with skeletal maturation, and albuminuria reversed. However, angiokeratomas increased in size and number.
Conclusion: The most recognizable early physical sign of FD is angiokeratoma, which can play a critical role in the detection of the disease. However, there is no compelling evidence that angiokeratoma can serve as a surrogate marker for the course of the disease or the efficacy of ERT.
Downloads
Article Details
Copyright (c) 2014 Roganovic J, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5: 30.
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11: 790-796.
Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, et al. (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157: 331-337.
Möhrenschlager M, Braun-Falco M, Ring J, Abeck D (2003) Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 4: 189-196.
Larralde M, Luna P. Fabry disease. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill; 2007. p. 1281-1288.
Bongiorno MR, Pistone G, Aricò M (2003) Fabry disease: enzyme replacement therapy. J Eur Acad Dermatol Venereol 17: 676-679.
Tsambaos D, Chroni E, Manolis A, Monastirli A, Pasmatzi E, et al. (2004) Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up. Acta Derm Venereol 84: 389-392.
Ries M, Schiffmann R (2005) Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement therapy on kidney function. Arch Dermatol 141: 904-905.
Fauchais AL, Prey S, Ouatara B, Vidal E, Sparsa A (2010) Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker? J Eur Acad Dermatol Venereol 24: 737-738.